首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

全球基因療法市場按類型、載體、基因類型、治療領域、交付方式和地區分類 - 預測至 2032 年

市場調查報告書

商品編碼

1663332

全球基因療法市場按類型、載體、基因類型、治療領域、交付方式和地區分類 - 預測至 2032 年

Gene Therapy Market by Type (Gene silencing), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (In-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032

出版日期: 2025年02月20日 | 出版商:

MarketsandMarkets | 英文 434 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球基因療法市場規模預計將從 2024 年的 88.5 億美元增至 2032 年的 365.5 億美元，預測期內（2024-2032 年）的複合年成長率為 19.4%。

基因治療市場的成長主要得益於主要企業對基因治療方法研發的研發投入不斷增加，以及新型基因療法核准數量的不斷增加。然而，複雜的法規結構和有關基因改造的道德問題正在抑制市場的成長。

研究範圍
調查年份	2022-2032
基準年	2023
預測期	2024-2032
單元	美元
部分	治療類型、載體、基因類型、治療領域、遞送方法、給藥途徑、最終用戶
目標區域	北美、歐洲、亞太地區、拉丁美洲、中東和非洲

“根據給藥途徑，靜脈注射途徑部分在 2023 年佔據最大佔有率。”

此細分市場的佔有率較大，主要由於靜脈注射基因療法的數量增加，這是由於靜脈注射的療效高，且目前核准並在市場上廣泛存在的靜脈基因治療產品。

“2024-2032年的預測期內，美國將繼續主導基因治療市場。”

美國是全球最大的生物製藥市場，也是生物製藥研究和投資的領導者。這是由於慢性病患者數量不斷增加、生物製藥重要性日益提高、醫療保健領域對安全優質產品的需求以及政府機構和製藥生物技術公司對生物醫學研究的投資和資金不斷增加。此外，該地區多個市場參與企業的既定存在也是支持市場成長的主要因素。這些主要企業包括Biogen Inc.（美國）、Alnylam Pharmaceuticals, Inc.（美國）、Sarepta Therapeutics, Inc.（美國）等。

本報告對全球基因治療市場進行了深入分析，包括關鍵促進因素和限制因素、競爭格局和未來趨勢。

介紹
市場動態
- 驅動程式
- 限制因素
- 機會
- 任務
技術分析
- 關鍵技術
- 互補技術
- 相關技術
價值鏈分析
供應鏈分析
- 知名公司
- 中小型企業
- 最終用戶
- 投資者、創投家和融資機構
- 監管機構
生態系分析
專利分析
管道分析
監管格局
- 各地區監管機構、政府機構及其他組織
- 法規結構
- 贖回情況
定價分析
- 平均銷售價格趨勢：依主要企業分類
- 各地區平均銷售價格趨勢
影響客戶業務的趨勢/干擾
重大會議和活動（2025-2026年）
波特五力分析
主要相關利益者和採購標準
投資金籌措場景
人工智慧對基因治療市場的影響

第6章基因治療市場依治療類型分類

介紹
基因靜默治療
細胞替代療法
基因增強治療
其他治療

第 7 章基因治療市場（依載體）

介紹
病毒載體
- 逆轉錄病毒載體
- AAV 載體
- 其他病毒載體
非病毒載體
- 寡核苷酸載體
- 其他非病毒載體

第 8 章基因治療市場（依基因類型）

介紹
不足
受體
抗原
細胞激素
腫瘤抑制因子
其他基因

第 9 章基因治療市場（依治療領域）

介紹
神經
瘤
血
其他治療領域

第 10 章基因治療市場以交付方式分類

介紹
內部交付
體外遞送

第 11 章基因治療市場依給藥途徑

介紹
靜脈注射
皮下
其他路線

第 12 章基因治療市場（依最終使用者分類）

介紹
醫院
專業中心
其他最終用戶

第13章基因治療市場（按地區）

介紹
北美洲
- 北美宏觀經濟分析
- 美國
- 加拿大
歐洲
- 歐洲宏觀經濟分析
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 瑞士
- 荷蘭
- 歐洲其他地區
亞太地區
- 亞太宏觀經濟分析
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 泰國
- 其他亞太地區
拉丁美洲
- 拉丁美洲宏觀經濟分析
- 巴西
- 墨西哥
- 其他拉丁美洲國家
中東
- 中東宏觀經濟分析
- 海灣合作理事會國家
- 其他中東地區
非洲

第14章競爭格局

概述
主要參與企業的策略/優勢（2022-2024）
收益分析（2021-2023）
市場佔有率分析（2023 年）
企業評估矩陣：主要企業（2023 年）
公司評估矩陣：Start-Ups/中小企業（2023 年）
估值及財務指標
品牌/產品比較
競爭場景

第15章公司簡介

介紹
主要企業
- BIOGEN INC.
- NOVARTIS AG
- ALNYLAM PHARMACEUTICALS, INC.
- SAREPTA THERAPEUTICS, INC.
- JAZZ PHARMACEUTICALS PLC
- FERRING BV
- PFIZER INC.
- AMGEN, INC.
- JOHNSON & JOHNSON SERVICES, INC.
- DAIICHI SANKYO COMPANY, LIMITED.
- BIOMARIN PHARMACEUTICAL INC.
- KYOWA KIRIN CO., LTD.
- NIPPON SHINYAKU CO., LTD.
- PTC THERAPEUTICS
- UNIQURE NV.
其他公司
- JUVENTAS CELL THERAPY LTD.
- CRISPR THERAPEUTICS
- BLUEBIRD BIO, INC.
- KRYSTAL BIOTECH, INC.
- SHANGHAI SUNWAY BIOTECH CO., LTD.
- JW (CAYMAN) THERAPEUTICS CO. LTD
- IASO BIOTECHNOLOGY
- CARSGEN THERAPEUTICS HOLDINGS LIMITED
- ADAPTIMMUNE
- SIBIONO GENETECH CO. LTD.
- ULTRAGENYX PHARMACEUTICAL INC.

第16章附錄

簡介目錄圖表

Product Code: BT 7506

The global gene therapy market is projected to reach USD 36.55 billion by 2032 from USD 8.85 billion in 2024, at a CAGR of 19.4% during the forecast period of 2024 to 2032. The growth of the gene therapy market has been significantly driven by increasing R&D investment by key players for the development gene therapy drugs and growing approval of novel gene therapies. However, complex regulatory frameworks and ethical concerns regarding genetic modifications are restraining market growth.

Scope of the Report
Years Considered for the Study	2022-2032
Base Year	2023
Forecast Period	2024-2032
Units Considered	Value (USD)
Segments	Therapy Type, Vector, Gene Type, Therapeutic Area, Delivery Method, Route of Administration, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The intravenous route segment accounted for the largest share by route of administration in 2023."

Based on route of administration, the gene therapy market is segmented into intravenous route, subcutaneous route and other routes. The intravenous route segment accounted for the largest share of the gene therapy market in 2023. The larger share of this segment is mainly attributed to the number of gene therapy administered through intravenous route is due to factors such as the high effectiveness of intravenous administration and high penetration of intravenous gene therapy currently approved and marketed products among others.

"The US has continued to dominate the gene therapy market during the forecast period of 2024-2032."

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from chronid disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:

Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Ferring B.V. (Switzerland), Pfizer Inc. (US), Amgen, Inc. (US), Johnson & Johnson Services, Inc. (US), Daiichi Sankyo Company, Limited. (Japan), BioMarin Pharmaceutical Inc. (US), Kyowa Kirin Co., Ltd. (Japan), Nippon Shinyaku Co., Ltd. (Japan), PTC Therapeutics (US), UniQure NV (Netherlands), Juventas Cell Therapy Ltd. (China), CRISPR Therapeutics (Switzerland), bluebird bio, Inc. (US), Krystal Biotech, Inc. (US), Shanghai Sunway Biotech Co., Ltd. (China), JW (Cayman) Therapeutics Co. Ltd (China), IASO Biotechnology (China), CARsgen Therapeutics Holdings Limited (China), Adaptimmune (UK), Sibiono GeneTech Co. Ltd. (China), and Ultragenyx Pharmaceutical Inc. (US).

Research Coverage:

This research report categorizes the gene therapy market by Therapy Type (Gene Silencing Therapy, Cell Replacement Therapy, Gene Augmentation Therapy and Other Therapies)), by Vector (Viral Vectors (Retroviral Vector (Gamma retroviral vectors, Lentiviral Vectors) AAV Vectors, and Other Viral Vectors), Non-viral Vectors (Oligonucleotides and Other Non-viral Vectors)), by Gene Type (Deficiency, Receptors, Antigen, Cytokine, Tumor Suppressor, and Othe Genes), by Therapeutic Area (Neurology, Oncology, Hematology and Other Therapeutic Areas), by Delivery Method (In Vivo and Ex Vivo), by Route of Administration (Intravenous Route, Subcutaneous Route, and Other Routes), by End User (Hospitals, Specialty Centers, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations and acquisitions, and recent developments associated with the gene therapy market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, Increasing investments in gene therapy research, Growing technological advancements, and Robust clinical trial pipeline for gene therapy), restraints (High cost of gene therapy products, Complex regulatory frameworks and ethical concerns regarding genetic modifications, and Limited manufacturing scalability), opportunities (Expansion into rare diseases and unmet needs, Increasing focus on precision medicine, and Advancements in gene therapy delivery technologies), and Challenges (Complex manufacturing process, Short shelf life and supply chain challenges, and Lack of reimbursement).
Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the gene therapy market.
Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene therapy market
Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the gene therapy market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY RESEARCH
  - 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY RESEARCH
  - 2.1.2.1 Insights of primary experts
2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 GENE THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE & COUNTRY (2024)
4.3 GENE THERAPY MARKET SHARE, BY END USER, 2024 VS 2032
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Growing demand for curative therapies for genetic disorders, rare diseases, and cancers
  - 5.2.1.2 Increasing investments in gene therapy research
  - 5.2.1.3 Technological advancements
  - 5.2.1.4 Robust clinical trial pipeline for gene therapy
- 5.2.2 RESTRAINTS
  - 5.2.2.1 High cost of gene therapy products
  - 5.2.2.2 Complex regulatory frameworks and ethical concerns regarding genetic modifications
  - 5.2.2.3 Limited manufacturing scalability
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Expansion into rare diseases and unmet needs
  - 5.2.3.2 Increasing focus on precision medicine
  - 5.2.3.3 Advancements in gene therapy delivery technologies
- 5.2.4 CHALLENGES
  - 5.2.4.1 Complex commercial manufacturing and scaling process
  - 5.2.4.2 Short shelf life and supply chain challenges
  - 5.2.4.3 Lack of reimbursement
5.3 TECHNOLOGY ANALYSIS
- 5.3.1 KEY TECHNOLOGIES
  - 5.3.1.1 CRISPR-Cas9
  - 5.3.1.2 RNA interference
  - 5.3.1.3 Viral vectors
- 5.3.2 COMPLEMENTARY TECHNOLOGIES
  - 5.3.2.1 Stem cell therapy
  - 5.3.2.2 Omics technologies
- 5.3.3 ADJACENT TECHNOLOGIES
  - 5.3.3.1 Nanoparticles
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
- 5.5.1 PROMINENT COMPANIES
- 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
- 5.5.3 END USERS
- 5.5.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
- 5.5.5 REGULATORY BODIES
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 PIPELINE ANALYSIS
5.9 REGULATORY LANDSCAPE
- 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
- 5.9.2 REGULATORY FRAMEWORK
- 5.9.3 REIMBURSEMENT SCENARIO
5.10 PRICING ANALYSIS
- 5.10.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
- 5.10.2 AVERAGE SELLING PRICE TREND, BY REGION
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 THREAT OF NEW ENTRANTS
- 5.13.2 THREAT OF SUBSTITUTES
- 5.13.3 BARGAINING POWER OF SUPPLIERS
- 5.13.4 BARGAINING POWER OF BUYERS
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF AI ON GENE THERAPY MARKET

6 GENE THERAPY MARKET, BY THERAPY TYPE

6.1 INTRODUCTION
6.2 GENE SILENCING THERAPY
- 6.2.1 FLEXIBILITY AND PRECISION OF GENE SILENCING THERAPIES TO SUPPORT GROWTH
6.3 CELL REPLACEMENT THERAPY
- 6.3.1 LONG-TERM EFFECT OF THERAPY TO SUPPORT GROWTH IN ADOPTION
6.4 GENE AUGMENTATION THERAPY
- 6.4.1 EFFECTIVENESS AGAINST MONOGENIC DISORDERS TO DRIVE MARKET
6.5 OTHER THERAPIES

7 GENE THERAPY MARKET, BY VECTOR

7.1 INTRODUCTION
7.2 VIRAL VECTORS
- 7.2.1 RETROVIRAL VECTORS
  - 7.2.1.1 Advantages of retroviral vectors to support market growth
  - 7.2.1.2 Gamma-retroviral vectors
    - 7.2.1.2.1 Availability of gamma-retroviral vectors to support market growth
  - 7.2.1.3 Lentiviral vectors
    - 7.2.1.3.1 North America to dominate lentiviral vectors market
- 7.2.2 AAV VECTORS
  - 7.2.2.1 Focus of clinical pipeline on adeno-associated viral vectors to drive growth
- 7.2.3 OTHER VIRAL VECTORS
7.3 NON-VIRAL VECTORS
- 7.3.1 OLIGONUCLEOTIDE VECTORS
  - 7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
- 7.3.2 OTHER NON-VIRAL VECTORS

8 GENE THERAPY MARKET, BY GENE TYPE

8.1 INTRODUCTION
8.2 DEFICIENCY
- 8.2.1 TECHNOLOGICAL ADVANCEMENT IN GENE THERAPIES TO BOOST GROWTH
8.3 RECEPTOR
- 8.3.1 INCREASING DEMAND FOR DEVELOPING RECEPTOR-BASED GENE THERAPY TO SUPPORT MARKET GROWTH
8.4 ANTIGEN
- 8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO PROPEL GROWTH
8.5 CYTOKINE
- 8.5.1 RISING R&D TO SUPPORT MARKET GROWTH
8.6 TUMOR SUPPRESSOR
- 8.6.1 RISING PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
8.7 OTHER GENES

9 GENE THERAPY MARKET, BY THERAPEUTIC AREA

9.1 INTRODUCTION
9.2 NEUROLOGY
- 9.2.1 ENHANCED DELIVERY METHODS AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO BOOST MARKET GROWTH
9.3 ONCOLOGY
- 9.3.1 RISING BURDEN OF CANCER TO SUPPORT MARKET GROWTH
9.4 HEMATOLOGY
- 9.4.1 INCREASING PREVALENCE OF GENETIC BLOOD DISORDERS TO BOOST MARKET GROWTH
9.5 OTHER THERAPEUTIC AREAS

10 GENE THERAPY MARKET, BY DELIVERY METHOD

10.1 INTRODUCTION
10.2 IN VIVO DELIVERY
- 10.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
10.3 EX VIVO DELIVERY
- 10.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH

11 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION

11.1 INTRODUCTION
11.2 INTRAVENOUS ROUTE
- 11.2.1 HIGH EFFECTIVENESS AND LARGE SHARE OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
11.3 SUBCUTANEOUS ROUTE
- 11.3.1 DEVELOPMENT OF IMPROVED DELIVERY DEVICES TO SUPPORT MARKET GROWTH
11.4 OTHER ROUTES

12 GENE THERAPY MARKET, BY END USER

12.1 INTRODUCTION
12.2 HOSPITALS
- 12.2.1 GROWING DEMAND FOR ADVANCED THERAPIES TO BOOST MARKET
12.3 SPECIALTY CENTERS
- 12.3.1 ADVANCEMENTS IN GENE THERAPY TECHNOLOGIES TO SUPPORT MARKET GROWTH
12.4 OTHER END USERS

13 GENE THERAPY MARKET, BY REGION

13.1 INTRODUCTION
13.2 NORTH AMERICA
- 13.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
- 13.2.2 US
  - 13.2.2.1 US to dominate North American market during forecast period
- 13.2.3 CANADA
  - 13.2.3.1 Government support for expanding manufacturing facilities to propel market growth
13.3 EUROPE
- 13.3.1 EUROPE: MACROECONOMIC ANALYSIS
- 13.3.2 GERMANY
  - 13.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market
- 13.3.3 UK
  - 13.3.3.1 Strong government support to propel market growth
- 13.3.4 FRANCE
  - 13.3.4.1 Government investment in pharmaceutical industry to drive growth
- 13.3.5 ITALY
  - 13.3.5.1 Initiatives for gene therapy development to drive growth
- 13.3.6 SPAIN
  - 13.3.6.1 Expansion of biomanufacturing facilities to support market growth
- 13.3.7 SWITZERLAND
  - 13.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market growth
- 13.3.8 NETHERLANDS
  - 13.3.8.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
- 13.3.9 REST OF EUROPE
13.4 ASIA PACIFIC
- 13.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
- 13.4.2 CHINA
  - 13.4.2.1 China to dominate Asia Pacific market during forecast period
- 13.4.3 JAPAN
  - 13.4.3.1 Increasing initiatives supporting gene therapy adoption to propel market growth
- 13.4.4 INDIA
  - 13.4.4.1 Favorable scenario for foreign direct investment to favor market growth
- 13.4.5 AUSTRALIA
  - 13.4.5.1 Increasing demand for innovative therapies to propel market
- 13.4.6 SOUTH KOREA
  - 13.4.6.1 Increased export of drugs to support market growth
- 13.4.7 THAILAND
  - 13.4.7.1 Favorable government policies to propel adoption of advanced therapies
- 13.4.8 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
- 13.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
- 13.5.2 BRAZIL
  - 13.5.2.1 Brazil to dominate LATAM market during forecast period
- 13.5.3 MEXICO
  - 13.5.3.1 Rising demand for chronic disease treatment to support market growth
- 13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
- 13.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
- 13.6.2 GCC COUNTRIES
  - 13.6.2.1 Saudi Arabia
    - 13.6.2.1.1 Growing healthcare expenditure to boost market growth
  - 13.6.2.2 UAE
    - 13.6.2.2.1 Growing focus on genetic medicine development projects to drive market
  - 13.6.2.3 Rest of GCC Countries
- 13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
- 13.7.1 HIGH GROWTH POTENTIAL OF AFRICAN MARKETS TO ATTRACT KEY PLAYERS
- 13.7.2 AFRICA: MACROECONOMIC ANALYSIS

14 COMPETITIVE LANDSCAPE

14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2024
- 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET, 2022-2024
14.3 REVENUE ANALYSIS, 2021-2023
14.4 MARKET SHARE ANALYSIS, 2023
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 14.5.1 STARS
- 14.5.2 EMERGING LEADERS
- 14.5.3 PERVASIVE PLAYERS
- 14.5.4 PARTICIPANTS
- 14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2023
  - 14.5.5.1 Company footprint
  - 14.5.5.2 Region footprint
  - 14.5.5.3 Therapy type footprint
  - 14.5.5.4 Therapeutic area footprint
  - 14.5.5.5 Route of administration footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 14.6.1 PROGRESSIVE COMPANIES
- 14.6.2 RESPONSIVE COMPANIES
- 14.6.3 DYNAMIC COMPANIES
- 14.6.4 STARTING BLOCKS
- 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  - 14.6.5.1 Detailed list of key startups/SMEs
  - 14.6.5.2 Competitive benchmarking of key startups/SMEs
14.7 VALUATION & FINANCIAL METRICS
- 14.7.1 FINANCIAL METRICS
- 14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
- 14.9.1 PRODUCT APPROVALS
- 14.9.2 DEALS
- 14.9.3 EXPANSIONS

15 COMPANY PROFILES

15.1 INTRODUCTION
15.2 KEY PLAYERS
- 15.2.1 BIOGEN INC.
  - 15.2.1.1 Business overview
  - 15.2.1.2 Products offered
  - 15.2.1.3 Recent developments
    - 15.2.1.3.1 Deals
  - 15.2.1.4 MnM view
    - 15.2.1.4.1 Key strengths
    - 15.2.1.4.2 Strategic choices
    - 15.2.1.4.3 Weaknesses and competitive threats
- 15.2.2 NOVARTIS AG
  - 15.2.2.1 Business overview
  - 15.2.2.2 Products offered
  - 15.2.2.3 Recent developments
    - 15.2.2.3.1 Deals
    - 15.2.2.3.2 Expansions
    - 15.2.2.3.3 Other developments
  - 15.2.2.4 MnM view
    - 15.2.2.4.1 Key strengths
    - 15.2.2.4.2 Strategic choices
    - 15.2.2.4.3 Weaknesses and competitive threats
- 15.2.3 ALNYLAM PHARMACEUTICALS, INC.
  - 15.2.3.1 Business overview
  - 15.2.3.2 Products offered
  - 15.2.3.3 Recent developments
    - 15.2.3.3.1 Product approvals
    - 15.2.3.3.2 Deals
    - 15.2.3.3.3 Other developments
  - 15.2.3.4 MnM view
    - 15.2.3.4.1 Key strengths
    - 15.2.3.4.2 Strategic choices
    - 15.2.3.4.3 Weaknesses and competitive threats
- 15.2.4 SAREPTA THERAPEUTICS, INC.
  - 15.2.4.1 Business overview
  - 15.2.4.2 Products offered
  - 15.2.4.3 Recent developments
    - 15.2.4.3.1 Product approvals
    - 15.2.4.3.2 Deals
  - 15.2.4.4 MnM view
    - 15.2.4.4.1 Key strengths
    - 15.2.4.4.2 Strategic choices
    - 15.2.4.4.3 Weaknesses and competitive threats
- 15.2.5 JAZZ PHARMACEUTICALS PLC
  - 15.2.5.1 Business overview
  - 15.2.5.2 Products offered
  - 15.2.5.3 Recent developments
    - 15.2.5.3.1 Expansions
  - 15.2.5.4 MnM view
    - 15.2.5.4.1 Key strengths
    - 15.2.5.4.2 Strategic choices
    - 15.2.5.4.3 Weaknesses and competitive threats
- 15.2.6 FERRING B.V.
  - 15.2.6.1 Business overview
  - 15.2.6.2 Products offered
  - 15.2.6.3 Recent developments
    - 15.2.6.3.1 Product approvals
    - 15.2.6.3.2 Deals
    - 15.2.6.3.3 Expansions
- 15.2.7 PFIZER INC.
  - 15.2.7.1 Business overview
  - 15.2.7.2 Products offered
  - 15.2.7.3 Recent developments
    - 15.2.7.3.1 Product approvals
    - 15.2.7.3.2 Deals
- 15.2.8 AMGEN, INC.
  - 15.2.8.1 Business overview
  - 15.2.8.2 Products offered
  - 15.2.8.3 Recent developments
    - 15.2.8.3.1 Deals
    - 15.2.8.3.2 Expansions
- 15.2.9 JOHNSON & JOHNSON SERVICES, INC.
  - 15.2.9.1 Business overview
  - 15.2.9.2 Products offered
  - 15.2.9.3 Recent developments
    - 15.2.9.3.1 Deals
    - 15.2.9.3.2 Other developments
- 15.2.10 DAIICHI SANKYO COMPANY, LIMITED.
  - 15.2.10.1 Business overview
  - 15.2.10.2 Products offered
- 15.2.11 BIOMARIN PHARMACEUTICAL INC.
  - 15.2.11.1 Business overview
  - 15.2.11.2 Products offered
  - 15.2.11.3 Recent developments
    - 15.2.11.3.1 Product approvals
    - 15.2.11.3.2 Expansions
- 15.2.12 KYOWA KIRIN CO., LTD.
  - 15.2.12.1 Business overview
  - 15.2.12.2 Products offered
  - 15.2.12.3 Recent developments
    - 15.2.12.3.1 Product approvals
    - 15.2.12.3.2 Deals
- 15.2.13 NIPPON SHINYAKU CO., LTD.
  - 15.2.13.1 Business overview
  - 15.2.13.2 Products offered
  - 15.2.13.3 Recent developments
    - 15.2.13.3.1 Deals
- 15.2.14 PTC THERAPEUTICS
  - 15.2.14.1 Business overview
  - 15.2.14.2 Products offered
  - 15.2.14.3 Recent developments
    - 15.2.14.3.1 Product approvals
- 15.2.15 UNIQURE NV.
  - 15.2.15.1 Business overview
  - 15.2.15.2 Products offered
  - 15.2.15.3 Recent developments
    - 15.2.15.3.1 Deals
15.3 OTHER PLAYERS
- 15.3.1 JUVENTAS CELL THERAPY LTD.
- 15.3.2 CRISPR THERAPEUTICS
- 15.3.3 BLUEBIRD BIO, INC.
- 15.3.4 KRYSTAL BIOTECH, INC.
- 15.3.5 SHANGHAI SUNWAY BIOTECH CO., LTD.
- 15.3.6 JW (CAYMAN) THERAPEUTICS CO. LTD
- 15.3.7 IASO BIOTECHNOLOGY
- 15.3.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED
- 15.3.9 ADAPTIMMUNE
- 15.3.10 SIBIONO GENETECH CO. LTD.
- 15.3.11 ULTRAGENYX PHARMACEUTICAL INC.

16 APPENDIX

16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS

簡介目錄圖表

List of Tables

TABLE 1 GENE THERAPY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 3 GENE THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 4 GENE THERAPY MARKET: KEY PRODUCT APPROVALS, 2022-2024
TABLE 5 GENE THERAPY MARKET: INVESTMENTS AND FINANCING BY STARTUPS, 2024
TABLE 6 GENE THERAPY MARKET: LIST OF ADVANCED PLATFORMS LAUNCHED IN 2022-2024
TABLE 7 NUMBER OF CLINICAL TRIALS FOR GENE THERAPY DRUGS, 2024
TABLE 8 COST OF KEY GENE THERAPY PRODUCTS, 2024
TABLE 9 GENE THERAPY MARKET: RAW MATERIAL VENDORS
TABLE 10 GENE THERAPY MARKET: PRODUCT VENDORS
TABLE 11 GENE THERAPY MARKET: ROLE OF END USERS
TABLE 12 GENE THERAPY MARKET: REGULATORY BODIES
TABLE 13 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS, 2023-2024
TABLE 14 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 COUNTRY-WISE REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS
TABLE 20 US: REIMBURSEMENT CODES FOR GENE THERAPY PRODUCTS
TABLE 21 EUROPE: REIMBURSEMENT SCENARIO FOR GENE THERAPY PRODUCTS, BY COUNTRY
TABLE 22 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY KEY PLAYER, 2022-2024 (USD)
TABLE 23 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY REGION, 2022-2024 (USD)
TABLE 24 GENE THERAPY MARKET: KEY CONFERENCES & EVENTS, 2025-2026
TABLE 25 GENE THERAPY MARKET: IMPACT OF PORTER'S FIVE FORCES
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 27 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER
TABLE 28 GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 29 GENE SILENCING THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 30 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 31 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 32 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 33 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 34 MIDDLE EAST: GENE SILENCING THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 35 GCC COUNTRIES: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 36 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 37 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 38 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 39 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 40 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 41 MIDDLE EAST: CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 42 GCC COUNTRIES: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 43 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 44 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 45 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 46 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 47 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 48 MIDDLE EAST: GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 49 GCC COUNTRIES: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 50 OTHER GENE THERAPIES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 51 NORTH AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 52 EUROPE: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 53 ASIA PACIFIC: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 54 LATIN AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 55 MIDDLE EAST: OTHER GENE THERAPIES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 56 GCC COUNTRIES: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 57 GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 58 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 59 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 60 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 61 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 62 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 63 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 64 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 65 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 66 RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 67 RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 68 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 69 EUROPE: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 70 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 71 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 72 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 73 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 74 GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 75 NORTH AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 76 EUROPE: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 77 ASIA PACIFIC: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 78 LATIN AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 79 MIDDLE EAST: GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 80 GCC COUNTRIES: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 81 LENTIVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 82 NORTH AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 83 EUROPE: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 84 ASIA PACIFIC: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 85 LATIN AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 86 MIDDLE EAST: LENTIVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 87 GCC COUNTRIES: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 88 AAV VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 89 NORTH AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 90 EUROPE: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 91 ASIA PACIFIC: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 92 LATIN AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 93 MIDDLE EAST: AAV VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 94 GCC COUNTRIES: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 95 OTHER VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 96 NORTH AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 97 EUROPE: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 98 ASIA PACIFIC: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 99 LATIN AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 100 MIDDLE EAST: OTHER VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 101 GCC COUNTRIES: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 102 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 103 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 104 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 105 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 106 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 107 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 108 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 109 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 110 OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 112 EUROPE: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 117 OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 118 NORTH AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 119 EUROPE: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 120 ASIA PACIFIC: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 121 LATIN AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 122 MIDDLE EAST: OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 123 GCC COUNTRIES: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 124 GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 125 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 126 NORTH AMERICA: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 127 EUROPE: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 128 ASIA PACIFIC: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 129 LATIN AMERICA: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 130 MIDDLE EAST: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY REGION, 2022-2032 (USD MILLION)
TABLE 131 GCC COUNTRIES: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 132 RECEPTOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 133 NORTH AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 134 EUROPE: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 135 ASIA PACIFIC: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 136 LATIN AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 137 MIDDLE EAST: RECEPTOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 138 GCC COUNTRIES: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 139 ANTIGEN GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 140 NORTH AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 141 EUROPE: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 142 ASIA PACIFIC: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 143 LATIN AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 144 MIDDLE EAST: ANTIGEN GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 145 GCC COUNTRIES: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 146 CYTOKINE GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 147 NORTH AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 148 EUROPE: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 149 ASIA PACIFIC: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 150 LATIN AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 151 MIDDLE EAST: CYTOKINE GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 152 GCC COUNTRIES: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 153 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 154 NORTH AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 155 EUROPE: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 156 ASIA PACIFIC: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 157 LATIN AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 158 MIDDLE EAST: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 159 GCC COUNTRIES: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 160 GENE THERAPY MARKET FOR OTHER GENES, BY REGION, 2022-2032 (USD MILLION)
TABLE 161 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 162 EUROPE: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 163 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 164 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 165 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER GENES, BY REGION, 2022-2032 (USD MILLION)
TABLE 166 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 167 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 168 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2022-2032 (USD MILLION)
TABLE 169 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 170 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 171 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 172 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 173 MIDDLE EAST: GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2022-2032 (USD MILLION)
TABLE 174 GCC COUNTRIES: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 175 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022-2032 (USD MILLION)
TABLE 176 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 177 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 178 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 179 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 180 MIDDLE EAST: GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022-2032 (USD MILLION)
TABLE 181 GCC COUNTRIES: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 182 GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION, 2022-2032 (USD MILLION)
TABLE 183 NORTH AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 184 EUROPE: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 185 ASIA PACIFIC: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 186 LATIN AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 187 MIDDLE EAST: GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION, 2022-2032 (USD MILLION)
TABLE 188 GCC COUNTRIES: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 189 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2032 (USD MILLION)
TABLE 190 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 191 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 192 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 193 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 194 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2032 (USD MILLION)
TABLE 195 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 196 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 197 IN VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS
TABLE 198 IN VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 199 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 200 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 201 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 202 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 203 MIDDLE EAST: IN VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 204 GCC COUNTRIES: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 205 EX VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS
TABLE 206 EX VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 207 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 208 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 209 APAC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 210 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 211 MIDDLE EAST: EX VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 212 GCC COUNTRIES: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 213 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 214 EXAMPLES OF INTRAVENOUSLY DELIVERED GENE THERAPY
TABLE 215 INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 216 NORTH AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 217 EUROPE: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 218 ASIA PACIFIC: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 219 LATIN AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 220 MIDDLE EAST: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 221 GCC COUNTRIES: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 222 SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 223 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 224 EUROPE: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 225 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 226 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 227 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 228 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 229 EXAMPLE OF GENE THERAPIES ADMINISTERED THROUGH OTHER ROUTES
TABLE 230 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
TABLE 231 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 232 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 233 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 234 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 235 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
TABLE 236 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 237 GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 238 GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
TABLE 239 NORTH AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 240 EUROPE: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 241 ASIA PACIFIC: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 242 LATIN AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 243 MIDDLE EAST: GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
TABLE 244 GCC COUNTRIES: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 245 GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2032 (USD MILLION)
TABLE 246 NORTH AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 247 EUROPE: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 248 ASIA PACIFIC: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 249 LATIN AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 250 MIDDLE EAST: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2032 (USD MILLION)
TABLE 251 GCC COUNTRIES: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 252 GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022-2032 (USD MILLION)
TABLE 253 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 254 EUROPE: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 255 ASIA PACIFIC GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 256 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 257 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022-2032 (USD MILLION)
TABLE 258 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 259 GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 260 NORTH AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
TABLE 261 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 262 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 263 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 264 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 265 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 266 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 267 NORTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 268 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 269 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 270 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 271 NORTH AMERICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 272 US FDA APPROVALS FOR GENE THERAPY PRODUCTS, 2022-2024
TABLE 273 US: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 274 US: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 275 US: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 276 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 277 US: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 278 US: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 279 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 280 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 281 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 282 US: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 283 CANADA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 284 CANADA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 285 CANADA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 286 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 287 CANADA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 288 CANADA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 289 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 290 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 291 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 292 CANADA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 293 EUROPE: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
TABLE 294 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 295 EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 296 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 297 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 298 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 299 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 300 EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 301 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 302 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 303 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 304 EUROPE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 305 GERMANY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 306 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 307 GERMANY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 308 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 309 GERMANY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 310 GERMANY: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 311 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 312 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 313 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 314 GERMANY: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 315 UK: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 316 UK: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 317 UK: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 318 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 319 UK: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 320 UK: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 321 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 322 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 323 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 324 UK: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 325 FRANCE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 326 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 327 FRANCE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 328 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 329 FRANCE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 330 FRANCE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 331 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 332 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 333 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 334 FRANCE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 335 ITALY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 336 ITALY: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 337 ITALY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 338 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 339 ITALY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 340 ITALY: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 341 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 342 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 343 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 344 ITALY: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 345 SPAIN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 346 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 347 SPAIN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 348 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 349 SPAIN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 350 SPAIN: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 351 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 352 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 353 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 354 SPAIN: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 355 SWITZERLAND: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 356 SWITZERLAND: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 357 SWITZERLAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 358 SWITZERLAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 359 SWITZERLAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 360 SWITZERLAND: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 361 SWITZERLAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 362 SWITZERLAND: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 363 SWITZERLAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 364 SWITZERLAND: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 365 NETHERLANDS: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 366 NETHERLANDS: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 367 NETHERLANDS: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 368 NETHERLANDS: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 369 NETHERLANDS: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 370 NETHERLANDS: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 371 NETHERLANDS: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 372 NETHERLANDS: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 373 NETHERLANDS: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 374 NETHERLANDS: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 375 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 376 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 377 REST OF EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 378 REST OF EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 379 REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 380 REST OF EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 381 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 382 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 383 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 384 REST OF EUROPE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 385 ASIA PACIFIC: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
TABLE 386 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 387 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 388 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 389 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 390 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 391 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 392 ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 393 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 394 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 395 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 396 ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 397 CHINA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 398 CHINA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 399 CHINA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 400 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 401 CHINA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 402 CHINA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 403 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 404 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 405 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 406 CHINA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 407 JAPAN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 408 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 409 JAPAN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 410 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 411 JAPAN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 412 JAPAN: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 413 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 414 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 415 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 416 JAPAN: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 417 INDIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 418 INDIA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 419 INDIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 420 INDIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 421 INDIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 422 INDIA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 423 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 424 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 425 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 426 INDIA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 427 AUSTRALIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 428 AUSTRALIA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 429 AUSTRALIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 430 AUSTRALIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 431 AUSTRALIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 432 AUSTRALIA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 433 AUSTRALIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 434 AUSTRALIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 435 AUSTRALIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 436 AUSTRALIA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 437 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 438 SOUTH KOREA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 439 SOUTH KOREA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 440 SOUTH KOREA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 441 SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 442 SOUTH KOREA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 443 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 444 SOUTH KOREA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 445 SOUTH KOREA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 446 SOUTH KOREA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 447 THAILAND: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 448 THAILAND: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 449 THAILAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 450 THAILAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 451 THAILAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 452 THAILAND: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 453 THAILAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 454 THAILAND: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 455 THAILAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 456 THAILAND: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 457 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 458 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 459 REST OF ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 460 REST OF ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE 2022-2032 (USD MILLION)
TABLE 461 REST OF ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 462 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 463 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 464 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 465 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 466 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 467 LATIN AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
TABLE 468 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 469 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 470 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 471 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 472 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 473 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 474 LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 475 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 476 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 477 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 478 LATIN AMERICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 479 BRAZIL: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 480 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 481 BRAZIL: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 482 BRAZIL: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 483 BRAZIL: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 484 BRAZIL: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 485 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 486 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 487 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 488 BRAZIL: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 489 MEXICO: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 490 MEXICO: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 491 MEXICO: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 492 MEXICO: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 493 MEXICO: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 494 MEXICO: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 495 MEXICO: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 496 MEXICO: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 497 MEXICO: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 498 MEXICO: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 499 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 500 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 501 REST OF LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 502 REST OF LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 503 REST OF LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 504 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 505 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 506 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 507 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 508 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 509 MIDDLE EAST: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
TABLE 510 MIDDLE EAST: GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 511 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 512 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 513 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 514 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 515 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 516 MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 517 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 518 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 519 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 520 MIDDLE EAST: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 521 GCC COUNTRIES: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 522 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 523 GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 524 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 525 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 526 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 527 GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 528 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 529 GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 530 GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 531 GCC COUNTRIES: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 532 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 533 SAUDI ARABIA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 534 SAUDI ARABIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 535 SAUDI ARABIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 536 SAUDI ARABIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 537 SAUDI ARABIA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 538 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 539 SAUDI ARABIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 540 SAUDI ARABIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 541 SAUDI ARABIA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 542 UAE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 543 UAE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 544 UAE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 545 UAE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 546 UAE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 547 UAE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 548 UAE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 549 UAE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 550 UAE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 551 UAE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 552 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 553 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 554 REST OF GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 555 REST OF GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 556 REST OF GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 557 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 558 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 559 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 560 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 561 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 562 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 563 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 564 REST OF MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 565 REST OF MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 566 REST OF MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 567 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 568 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 569 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 570 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 571 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 572 AFRICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
TABLE 573 AFRICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
TABLE 574 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
TABLE 575 AFRICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 576 AFRICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 577 AFRICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 578 AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
TABLE 579 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
TABLE 580 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
TABLE 581 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 582 AFRICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 583 STRATEGIES DEPLOYED BY KEY COMPANIES IN GENE THERAPY MARKET
TABLE 584 GENE THERAPY MARKET: DEGREE OF COMPETITION
TABLE 585 GENE THERAPY MARKET: REGION FOOTPRINT
TABLE 586 GENE THERAPY MARKET: THERAPY TYPE FOOTPRINT
TABLE 587 GENE THERAPY MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 588 GENE THERAPY MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 589 GENE THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 590 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 591 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 592 GENE THERAPY MARKET: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 593 GENE THERAPY MARKET: EXPANSIONS, JANUARY 2022-DECEMBER 2024
TABLE 594 BIOGEN: COMPANY OVERVIEW
TABLE 595 BIOGEN: PRODUCTS OFFERED
TABLE 596 BIOGEN: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 597 NOVARTIS: COMPANY OVERVIEW
TABLE 598 NOVARTIS: PRODUCTS OFFERED
TABLE 599 NOVARTIS: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 600 NOVARTIS: EXPANSIONS, JANUARY 2022-DECEMBER 2024
TABLE 601 NOVARTIS: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2024
TABLE 602 ALNYLAM PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 603 ALNYLAM PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 604 ALNYLAM PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 605 ALNYLAM PHARMACEUTICALS: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 606 ALNYLAM PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2024
TABLE 607 SAREPTA THERAPEUTICS: COMPANY OVERVIEW
TABLE 608 SAREPTA THERAPEUTICS: PRODUCTS OFFERED
TABLE 609 SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 610 SAREPTA THERAPEUTICS: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 611 JAZZ PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 612 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 613 JAZZ PHARMACEUTICALS: EXPANSIONS, JANUARY 2022-DECEMBER 2024
TABLE 614 FERRING: COMPANY OVERVIEW
TABLE 615 FERRING: PRODUCTS OFFERED
TABLE 616 FERRING: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 617 FERRING: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 618 FERRING: EXPANSIONS, JANUARY 2022-DECEMBER 2024
TABLE 619 PFIZER: COMPANY OVERVIEW
TABLE 620 PFIZER: PRODUCTS OFFERED
TABLE 621 PFIZER: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 622 PFIZER: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 623 AMGEN: COMPANY OVERVIEW
TABLE 624 AMGEN: PRODUCTS OFFERED
TABLE 625 AMGEN: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 626 AMGEN: EXPANSIONS, JANUARY 2022-DECEMBER 2024
TABLE 627 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW
TABLE 628 JOHNSON & JOHNSON SERVICES: PRODUCTS OFFERED
TABLE 629 JOHNSON & JOHNSON SERVICES: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 630 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2024
TABLE 631 DAIICHI SANKYO COMPANY: COMPANY OVERVIEW
TABLE 632 DAIICHI SANKYO COMPANY: PRODUCTS OFFERED
TABLE 633 BIOMARIN PHARMACEUTICAL: COMPANY OVERVIEW
TABLE 634 BIOMARIN PHARMACEUTICAL: PRODUCTS OFFERED
TABLE 635 BIOMARIN PHARMACEUTICAL: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 636 BIOMARIN PHARMACEUTICAL: EXPANSIONS, JANUARY 2022-DECEMBER 2024
TABLE 637 KYOWA KIRIN: COMPANY OVERVIEW
TABLE 638 KYOWA KIRIN: PRODUCTS OFFERED
TABLE 639 KYOWA KIRIN: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 640 KYOWA KIRIN: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 641 NIPPON SHINYAKU: COMPANY OVERVIEW
TABLE 642 NIPPON SHINYAKU: PRODUCTS OFFERED
TABLE 643 NIPPON SHINYAKU: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 644 PTC THERAPEUTICS: COMPANY OVERVIEW
TABLE 645 PTC THERAPEUTICS: PRODUCTS OFFERED
TABLE 646 PTC THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
TABLE 647 UNIQURE: COMPANY OVERVIEW
TABLE 648 UNIQURE: PRODUCTS OFFERED
TABLE 649 UNIQURE: DEALS, JANUARY 2022-DECEMBER 2024
TABLE 650 JUVENTAS CELL THERAPY: COMPANY OVERVIEW
TABLE 651 CRISPR THERAPEUTICS: COMPANY OVERVIEW
TABLE 652 BLUEBIRD BIO: COMPANY OVERVIEW
TABLE 653 KRYSTAL BIOTECH: COMPANY OVERVIEW
TABLE 654 SHANGHAI SUNWAY BIOTECH: COMPANY OVERVIEW
TABLE 655 JW (CAYMAN) THERAPEUTICS: COMPANY OVERVIEW
TABLE 656 IASO BIOTECHNOLOGY: COMPANY OVERVIEW
TABLE 657 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
TABLE 658 ADAPTIMMUNE: COMPANY OVERVIEW
TABLE 659 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
TABLE 660 ULTRAGENYX PHARMACEUTICAL INC.: COMPANY OVERVIEW

List of Figures

FIGURE 1 GENE THERAPY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 GENE THERAPY MARKET: YEARS CONSIDERED
FIGURE 3 RESEARCH DESIGN
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: GENE THERAPY MARKET
FIGURE 5 GENE THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOVARTIS AG: REVENUE SHARE ANALYSIS (2023)
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9 GENE THERAPY MARKET: CAGR PROJECTIONS
FIGURE 10 DATA TRIANGULATION METHODOLOGY
FIGURE 11 GENE THERAPY MARKET, BY THERAPY TYPE, 2024 VS. 2032 (USD MILLION)
FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2024 VS. 2032 (USD MILLION)
FIGURE 13 GENE THERAPY MARKET, BY GENE TYPE, 2024 VS. 2032 (USD MILLION)
FIGURE 14 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2032 (USD MILLION)
FIGURE 15 GENE THERAPY MARKET, BY DELIVERY METHOD, 2024 VS. 2032 (USD MILLION)
FIGURE 16 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2024
FIGURE 17 GENE THERAPY MARKET, BY END USER, 2024 VS. 2032 (USD MILLION)
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET
FIGURE 19 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH-A KEY FACTOR DRIVING GROWTH
FIGURE 20 GENE SILENCING THERAPY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024
FIGURE 21 HOSPITALS TO DOMINATE END-USER MARKET TILL 2032
FIGURE 22 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 23 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24 GENE THERAPY MARKET: VALUE CHAIN ANALYSIS
FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 26 GENE THERAPY MARKET: ECOSYSTEM
FIGURE 27 PATENT ANALYSIS FOR GENE THERAPY MARKET, JANUARY 2014-DECEMBER 2024
FIGURE 28 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY TYPE, 2022-2024 (USD)
FIGURE 29 AVERAGE SELLING PRICE OF GENE THERAPIES, BY REGION, 2023 (USD)
FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
FIGURE 31 GENE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD
FIGURE 33 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER
FIGURE 34 GENE THERAPY MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 35 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
FIGURE 36 NIH FUNDING, 2014-2024
FIGURE 37 EUROPE: GENE THERAPY MARKET SNAPSHOT
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
FIGURE 40 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 41 GENE THERAPY MARKET: COMPANY FOOTPRINT
FIGURE 42 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 43 EV/EBITDA OF KEY VENDORS
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 45 GENE THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 46 BIOGEN: COMPANY SNAPSHOT (2023)
FIGURE 47 NOVARTIS: COMPANY SNAPSHOT (2023)
FIGURE 48 ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT (2023)
FIGURE 49 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023)
FIGURE 50 JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT (2023)
FIGURE 51 FERRING: COMPANY SNAPSHOT (2023)
FIGURE 52 PFIZER: COMPANY SNAPSHOT (2023)
FIGURE 53 AMGEN: COMPANY SNAPSHOT (2023)
FIGURE 54 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT (2023)
FIGURE 55 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2023)
FIGURE 56 BIOMARIN PHARMACEUTICAL: COMPANY SNAPSHOT (2023)
FIGURE 57 KYOWA KIRIN: COMPANY SNAPSHOT (2023)
FIGURE 58 NIPPON SHINYAKU: COMPANY SNAPSHOT (2023)
FIGURE 59 PTC THERAPEUTICS: COMPANY SNAPSHOT (2023)
FIGURE 60 UNIQURE: COMPANY SNAPSHOT (2023)